Janux Therapeutics (JANX) financial statements
Janux Therapeutics reported revenue of $10M in fiscal 2025, up 28.8% a year over 4 years.
Net income was -$114M.
Free cash flow was -$83M.
The diluted share count rose 6671% over the period (dilution).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from Janux Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $0 | $4M | $9M | $8M | $11M | $10M |
| Research and development | $3M | $26M | $53M | $55M | $68M | $126M |
| Selling, general and admin | $2M | $10M | $22M | $26M | $41M | $42M |
| Operating income | -$5M | -$33M | -$67M | -$73M | -$99M | -$158M |
| Income tax | — | — | — | $0 | $0 | $0 |
| Net income | -$7M | -$33M | -$63M | -$58M | -$69M | -$114M |
| EPS (diluted) | -$7.41 | -$1.39 | -$1.52 | -$1.32 | -$1.28 | -$1.83 |
| Diluted shares | 1M | 24M | 41M | 44M | 54M | 62M |
| Operating margin | — | -905.4% | -779.0% | -902.9% | -933.6% | -1576.7% |
| Net margin | — | -898.3% | -732.2% | -721.2% | -651.6% | -1136.2% |
Balance sheet
Fiscal years, from Janux Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Cash and short-term investments | $8M | $375M | $327M | $344M | $1.0B | $967M |
| Receivables | $8M | $0 | $0 | $0 | — | $0 |
| Total current assets | $16M | $377M | $332M | $349M | $1.0B | $976M |
| Property, plant and equipment | $155,000 | $1M | $7M | $7M | $5M | $4M |
| Total assets | $16M | $380M | $364M | $380M | $1.1B | $1.0B |
| Total current liabilities | $3M | $13M | $17M | $13M | $17M | $25M |
| Total liabilities | $9M | $13M | $43M | $36M | $39M | $45M |
| Shareholders' equity | -$15M | $366M | $321M | $344M | $1.0B | $957M |
| Net debt | -$8M | -$36M | -$51M | -$19M | -$431M | -$52M |
Cash flow
Fiscal years, from Janux Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$4M | -$17M | -$43M | -$51M | -$44M | -$82M |
| Capital spending | $0 | $1M | $6M | $2M | $359,000 | $1M |
| Free cash flow | -$4M | -$18M | -$49M | -$52M | -$44M | -$83M |
| Stock-based compensation | $72,000 | $7M | $17M | $20M | $33M | $40M |
| Free cash flow margin | — | -507.5% | -573.2% | -648.6% | -417.2% | -832.8% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for JANX.
Open JANX in InvestinglyQuestions
What was Janux Therapeutics's revenue in 2025?
$10M in fiscal 2025, from its 10-K filing.
How much free cash flow does Janux Therapeutics generate?
-$83M in fiscal 2025 (operating cash flow minus capital spending).
From Janux Therapeutics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.